| 研究报告 |
|
|
|
|
| 应用改构的炭疽毒素作为靶向肿瘤细胞的药物递送系统及其效果评价 |
| 李炳娟1,2, 李玉霞1, 李北平1, 凌焱1, 周围1, 李伟东1, 林海龙1, 梁龙1, 刘刚1, 张景海2, 陈惠鹏1 |
1. 军事医学科学院生物工程研究所 北京 100071;
2. 沈阳药科大学 沈阳 110016 |
|
| Construction and Evaluation of the Mutated Anthrax Toxin Proteins as Drug Deliver System for Targeting Tumor Cells |
| LI Bing-juan1,2, LI Yu-xia1, LI Bei-ping1, LING Yan1, ZHOU Wei1, LI Wei-dong1, LIN Hai-long1, LIANG Long1, LIU Gang1, ZHANG Jin-hai2, CHEN Hui-peng1 |
1. Beijing Institute of Biotechnology, Beijing 100071, China;
2. Department of Life Science, ShenYang Pharmaceutical University, ShenYang 110016, China |
引用本文:
李炳娟, 李玉霞, 李北平, 凌焱, 周围, 李伟东, 林海龙, 梁龙, 刘刚, 张景海, 陈惠鹏. 应用改构的炭疽毒素作为靶向肿瘤细胞的药物递送系统及其效果评价[J]. 中国生物工程杂志, 2013, 33(4): 1-8.
LI Bing-juan, LI Yu-xia, LI Bei-ping, LING Yan, ZHOU Wei, LI Wei-dong, LIN Hai-long, LIANG Long, LIU Gang, ZHANG Jin-hai, CHEN Hui-peng. Construction and Evaluation of the Mutated Anthrax Toxin Proteins as Drug Deliver System for Targeting Tumor Cells. China Biotechnology, 2013, 33(4): 1-8.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/
或
https://manu60.magtech.com.cn/biotech/CN/Y2013/V33/I4/1
|
[1] Liu S, Bugge T H, Leppla S H, Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem, 2001,276(21):17976-17984.
[2] Mendes O, Kim H T, Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis, 2005,22(3): 237-246.
[3] Kim H J, Park C, Jung W H, et al. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med, 2006,47(3):333-342.
[4] Wiercinska E, Naber H, Pardali E, et al. The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat, 2011,(128):657-666.
[5] Kai Kessenbrock, Vicki Plaks, Zena Werb. Matrix metalloproteinases: regulators of the tumor microenvironment.Cell, 2010,4(141):52-67.
[6] Mekkawy A H, David L Morris, Pourgholam M H.Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol,2009,5(9):1478-1499.
[7] Carlo Petosa, John Coller R, Kurt R Klimpel, et al.Crystal structure of the anthrax toxin protective antigen.Nature, 1997,2(385):833-838.
[8] Roopali Roy, Jiang Yang, Marsha A Moses. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. Journal of Clinical Oncology,2009,11(27):5287-5297.
[9] Liu S, Wang H, Brooke M Currie. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. The Journal of Biological Chemistry, 2008, 1( 283):529-540.
[10] Jeffrey M Schafer, Diane E Peters, Thomas Morley. Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin. PLoS ONE,2011,5(6):1-9.
[11] Randall W Alfano, Stephen H Leppla, Shihui Liu, et al. Inhibition of tumor angiogenesis by the matrix metalloproteinaseactivated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Mol Cancer Ther, 2010,9(1): 190-201.
[12] Cunningham K, Lacy D B, Mogridge J, et al. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. Proc Natl Acad Sci USA, 2002,99(10): 7049-7053.
[13] Chvyrkova I, Zhang X C, Terzyan S. Lethal factor of anthrax toxin binds monomeric form of protective antigen. Biochem Biophys Res Commun, 2007,360(3): 690-695.
[14] Abrami L, Reig N, van der Goot F G, Anthrax toxin: the long and winding road that leads to the kill. Trends Microbiol, 2005,13(2): 72-78. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
